Faldaprevir

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Faldaprevir
Accession Number
DB11808
Type
Small Molecule
Groups
Investigational
Description

Faldaprevir has been investigated for the treatment of Chronic Hepatitis C.

Structure
Thumb
Synonyms
  • Faldaprévir
  • Faldaprevir
  • Faldaprevirum
External IDs
BI 201335 / BI-201335 / BI201335
Product Ingredients
IngredientUNIICASInChI Key
Faldaprevir sodium1494Q15E7Z1215856-44-2JYIOGGWFNHGWMN-CWNXUBRBSA-M
Categories
UNII
958X4J301A
CAS number
801283-95-4
Weight
Average: 869.821
Monoisotopic: 868.246510533
Chemical Formula
C40H49BrN6O9S
InChI Key
LLGDPTDZOVKFDU-XUHJSTDZSA-N
InChI
InChI=1S/C40H49BrN6O9S/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48)/t21-,23-,27+,32-,40-/m1/s1
IUPAC Name
(1R,2S)-1-[(2S,4R)-4-({8-bromo-7-methoxy-2-[2-(2-methylpropanamido)-1,3-thiazol-4-yl]quinolin-4-yl}oxy)-1-[(2S)-2-{[(cyclopentyloxy)carbonyl]amino}-3,3-dimethylbutanoyl]pyrrolidine-2-amido]-2-ethenylcyclopropane-1-carboxylic acid
SMILES
COC1=C(Br)C2=C(C=C1)C(O[C@@H]1C[C@H](N(C1)C(=O)[C@@H](NC(=O)OC1CCCC1)C(C)(C)C)C(=O)N[C@@]1(C[C@H]1C=C)C(O)=O)=CC(=N2)C1=CSC(NC(=O)C(C)C)=N1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Faldaprevir.
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Faldaprevir.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Faldaprevir.
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Faldaprevir.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Faldaprevir.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Faldaprevir.
Human adenovirus e serotype 4 strain cl-68578 antigenThe therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Faldaprevir.
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Faldaprevir.
Typhoid Vaccine LiveThe therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Faldaprevir.
Varicella Zoster Vaccine (Live/attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Faldaprevir.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
42601552
PubChem Substance
347828155
ChemSpider
26327117
BindingDB
50336545
ChEMBL
CHEMBL1241348
PharmGKB
PA166128132
HET
L4T
Wikipedia
Faldaprevir
ATC Codes
J05AP04 — Faldaprevir
PDB Entries
3p8n

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection3
1CompletedTreatmentHealthy Volunteers16
1CompletedTreatmentHepatitis C Viral Infection3
1CompletedTreatmentHepatitis C Viral Infection / Liver Cirrhosis1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
1TerminatedTreatmentHealthy Volunteers3
1TerminatedTreatmentImpaired kidney function1
1WithdrawnTreatmentHealthy Volunteers1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection5
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C Genotype 1 / Hepatitis C Viral Infection / Hepatitis C Virus (HCV) Infection1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C Genotype 4 / Hepatitis C Viral Infection / Hepatitis C Virus (HCV) Infection1
2CompletedTreatmentHepatitis C Viral Infection1
2CompletedTreatmentHepatitis C Viral Infection / Pharmacokinetics1
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection4
3CompletedTreatmentHepatitis C Viral Infection4
3WithdrawnTreatmentChronic Hepatitis C Virus (HCV) Infection2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00128 mg/mLALOGPS
logP4.43ALOGPS
logP6.51ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)3.39ChemAxon
pKa (Strongest Basic)1.11ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area198.38 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity212.25 m3·mol-1ChemAxon
Polarizability86.94 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Oligopeptides
Alternative Parents
Valine and derivatives / N-acyl-L-alpha-amino acids / Proline and derivatives / Alpha amino acid amides / Haloquinolines / Anisoles / Pyrrolidinecarboxamides / N-acylpyrrolidines / N-arylamides / 2,4-disubstituted thiazoles
show 17 more
Substituents
Alpha-oligopeptide / N-acyl-alpha amino acid or derivatives / Valine or derivatives / Proline or derivatives / N-acyl-alpha-amino acid / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Haloquinoline / Quinoline / Alpha-amino acid or derivatives
show 38 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:49 / Updated on December 02, 2019 09:11